Gemcitabine (G) plus cisplatin (C) is a highly active regimen in first-line treatment of metastatic breast cancer (MBC): Results of a multicenter phase II trial

被引：0
|
作者：
Fuentes, H
Calderillo, G
Alexander, F
Ramirez, M
Avila, E
Perez, L
Aguirre, C
机构：
[1] Inst Nacl Cancerol, SSA, Mexico City, DF, Mexico
[2] Hosp Gen Occidente Seguro Social, SSA, Oncol Serv, Guadalajara, Jalisco, Mexico
[3] IMSS, Unidad Morelos 1, Cuernavaca, Morelos, Mexico
[4] Ctr Med Potosi, Oncol & Radiotherapy Serv, San Luis Potosi, Mexico
[5] Clin ISSSTE, Oncol Serv, Ensenada, Baja California, Mexico
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80216-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [41] Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer.
    Alauddin, Z
    Shaharyar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 56S - 56S
  • [42] Phase II trial of first-line capecitabine plus cisplatin in patients with advanced/metastatic nasopharyngeal cancer (NPC)
    Chua, D.
    Ng, W.
    Yiu, H.
    Seetalarom, K.
    Kurnianda, J.
    Sze, W.
    Krishnan, G.
    Shotelersuk, K.
    Hong, R.
    Forster, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Capecitabine (X) plus trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): phase II trial results.
    Xu, L.
    Song, S.
    Zhu, J.
    Luo, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S102 - S102
  • [44] Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).
    Harbeck, N.
    Kaufmann, M.
    Siedentopf, F.
    Dalivoust, P.
    Debled, M.
    Robert, N. J.
    O'Shaughnessy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] A COMPARISON OF FIRST-LINE TREATMENT WITH GEMCITABINE PLUS DOCETAXEL VERSUS GEMCITABINE PLUS VINORELBINE IN WOMEN WITH METASTATIC BREAST CANCER
    Bensalem, A.
    Bouzid, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [46] Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+pts) as first-line treatment in metastatic breast cancer
    Peacock, N. W.
    Spigel, D. R.
    Mainwaring, M. G.
    Thompson, D. S.
    Simons, L.
    Rubin, M. S.
    McCleod, M.
    Harwin, W. N.
    Schreiber, F. J.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Xu, Binghe
    Jiang, Zefei
    Kim, Sung-Bae
    Yu, Shiying
    Feng, Jifeng
    Malzyner, Artur
    del Giglio, Auro
    Chung, Hyun C.
    Shen, Li Jun
    Pen, Daniel Lee Kay
    BREAST CANCER, 2011, 18 (03) : 203 - 212
  • [48] Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II GEICAM study
    Alba, E
    Antón, A
    Ribelles, N
    Pérez-Carrión, R
    López-Vega, J
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godés, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S66
  • [49] Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.
    Guardino, A. E.
    Chen, M.
    Levy, M.
    Chen, M.
    CANCER RESEARCH, 2009, 69 (24) : 853S - 853S
  • [50] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345